Table 1.
Demographic and clinical features of the patients with EOPD and LOPD.
| All (n = 332) | EOPD (n = 134) | EOPD with SCC (n = 25, 18.66%) | EOPD without SCC (n = 109, 81.34%) | LOPD (n = 198) | LOPD with SCC (n = 49, 24.74%) | LOPD without SCC (n = 149, 75.25%) | |
|---|---|---|---|---|---|---|---|
| Age (years) | 56.30 (46.70–65.50) | 44.72 (39.14–48.15) | 48.24 (44.64–49.14) | 43.68 (38.45–47.41) | 64.19 (57.43–70.91) | 63.93 (57.92–71.82) | 64.39 (57.30–70.36) |
| Male | 178 (53.61%) | 73 (54.48%) | 13 (52.00%) | 60 (55.05%) | 105 (53.03%) | 26 (53.06%) | 79 (53.02%) |
| Age at onset (years) | 54.39 (45.01–64.08) | 43.06 (37.15–46.75) | 47.14 (43.82–47.75) | 41.91 (35.98–45.94) | 61.93 (55.96–69.11) | 61.19 (57.09–70.11) | 62.31 (55.88–68.79) |
| Disease duration (years) | 1.45 (0.75–2.40) | 1.51 (0.91–2.76) | 1.33 (0.82–1.93) | 1.74 (0.91–3.02) | 1.37 (0.69–2.24) | 1.74 (0.75–3.01) | 1.27 (0.67–2.07) |
| Education (years) | 12 (9–16) | 12 (9–16) | 9 (8.5–13.5) | 12 (9–16) | 12 (9–15) | 12 (9–15) | 12 (9–15) |
| MDS-UPDRS III | 21 (14–29) | 19 (11–28) | 20 (14.5–29) | 19 (11–28) | 22 (16–29) | 28 (16–37) | 22 (15–27) |
| H&Y stage | 2 (1.5–2) | 2 (1.5–2) | 2 (1.5–2) | 2 (1.5–2) | 2 (2–2) | 2 (2–2.5) | 2 (2–2) |
| BMI | 23.08 (20.98–25.20) | 22.59 (20.76–24.76) | 22.89 (21.07–24.73) | 22.58 (20.70–24.87) | 23.65 (21.33–25.39) | 24.28 (21.44–26.18) | 23.45 (21.30–25.19) |
| Smoking | 87 (26.20%) | 40 (29.85%) | 8 (32.00%) | 32 (29.36%) | 47 (23.73%) | 9 (18.37%) | 38 (25.50%) |
| Drinking | 98 (29.52%) | 34 (25.37%) | 3 (12.00%) | 31 (28.44%) | 64 (32.32%) | 9 (18.37%) | 55 (36.91%) |
| MoCA | 27 (26–28) | 27 (26–29) | 26 (26–27) | 28 (27–29) | 27 (26–28) | 26 (26–27) | 27 (26–28) |
| Visuospatial/executive abilities | 5 (4–5) | 5 (4–5) | 4 (3–4) | 5 (4–5) | 5 (4–5) | 5 (4–5) | 4 (4–5) |
| Naming | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
| Attention | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) |
| Language | 3 (2–3) | 3 (3–3) | 3 (2.5–3) | 3 (3–3) | 3 (2–3) | 3 (2–3) | 3 (2–3) |
| Abstraction | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) |
| Memory | 4 (3–5) | 4 (3–5) | 3 (3–4) | 4 (3–5) | 4 (3–4) | 3 (3–4) | 4 (3–5) |
| Orientaion | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) | 6 (6–6) |
| FSS | 23 (9–43) | 29.5 (9–43) | 42 (24.5–48.5) | 24 (9–41) | 19.5 (9–43) | 35 (15–48) | 17 (9–40) |
| PDSS−2 | 5 (3–10) | 5 (2–9) | 8 (3.5–13.5) | 4 (2–7) | 6 (3–10.25) | 9 (5–16) | 5 (3–10) |
| RBD | 46 (13.85%) | 10 (7.46%) | 4 (16.00%) | 6 (5.50%) | 36 (18.18%) | 10 (20.41%) | 26 (17.45%) |
| LARS | −29 (−33 to −24) | −28 (−33 to −24) | −26 (−28.5 to −19.5) | −30 (−33 to −24) | −30 (−33 to −24) | −26 (−31.5 to −18) | −30 (−34 to −25) |
| HAMD | 5 (1.25–9) | 5 (2–10) | 4.5 (11–15) | 5 (2–9) | 4 (1–8) | 7 (4–15.5) | 3 (1–7) |
| HAMA | 5 (2–8) | 5 (2–9) | 8 (3.5–13) | 4 (2–7) | 4 (1–8) | 7 (5–13.5) | 3 (0–7) |
| ESS | 3 (1–7) | 4 (2–6) | 4 (3–8.5) | 4 (1–6) | 3 (1–8) | 3 (1–8) | 3 (2–8) |
| Orthostatic hypotension | 19 (5.72%) | 7 (5.22%) | 2 (8.00%) | 5 (4.59%) | 12 (6.06%) | 4 (8.16%) | 8 (5.37%) |
EOPD, early-onset Parkinson's disease; LOPD, late-onset Parkinson's disease; SCC, subjective cognitive complaints; H&Y stage, Hoehn and Yahr stage; MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease Rating Scale part III; BMI, body mass index; MoCA, Montreal Cognitive Assessment; HAMD, Hamilton Depression Rating Scale; HAMA, Hamilton Anxiety Rating Scale; FSS, Fatigue Severity Scale. LARS: Lille Apathy Rating Scale. PDSS-2: Parkinson's Disease Sleep Scale 2nd version. EDS: Excessive daytime sleepiness; RBD, rapid eye movement sleep behavior disorder; BMI, body mass index.